Nothing Special   »   [go: up one dir, main page]

ATE302616T1 - Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe - Google Patents

Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe

Info

Publication number
ATE302616T1
ATE302616T1 AT02747410T AT02747410T ATE302616T1 AT E302616 T1 ATE302616 T1 AT E302616T1 AT 02747410 T AT02747410 T AT 02747410T AT 02747410 T AT02747410 T AT 02747410T AT E302616 T1 ATE302616 T1 AT E302616T1
Authority
AT
Austria
Prior art keywords
active ingredients
controlled release
medicinal compositions
oral application
amphiphilicmatrix
Prior art date
Application number
AT02747410T
Other languages
English (en)
Inventor
Maria Gabriella Massironi
Original Assignee
Farmatron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmatron Ltd filed Critical Farmatron Ltd
Application granted granted Critical
Publication of ATE302616T1 publication Critical patent/ATE302616T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02747410T 2001-06-26 2002-06-19 Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe ATE302616T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001337A ITMI20011337A1 (it) 2001-06-26 2001-06-26 Composizioni farmaceutiche orali a rilascio modificato del principio attivo
PCT/EP2002/006749 WO2003002151A1 (en) 2001-06-26 2002-06-19 Oral pharmaceutical compositions with modified release of the active ingredient

Publications (1)

Publication Number Publication Date
ATE302616T1 true ATE302616T1 (de) 2005-09-15

Family

ID=11447930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02747410T ATE302616T1 (de) 2001-06-26 2002-06-19 Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe

Country Status (11)

Country Link
US (1) US7727551B2 (de)
EP (1) EP1401501B1 (de)
JP (1) JP4657601B2 (de)
AT (1) ATE302616T1 (de)
CA (1) CA2451379C (de)
DE (1) DE60205749T2 (de)
DK (1) DK1401501T3 (de)
ES (1) ES2248576T3 (de)
IT (1) ITMI20011337A1 (de)
PT (1) PT1401501E (de)
WO (1) WO2003002151A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CN1668284A (zh) * 2002-06-07 2005-09-14 兰贝克赛实验室有限公司 加巴喷丁的缓释口服剂型
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1510208A1 (de) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2543238A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
ITMI20032399A1 (it) 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
CA2585316C (en) * 2004-11-17 2013-06-25 Ares Trading S.A. Benzothiazole formulations and use thereof
UY29445A1 (es) * 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ES2288117B1 (es) * 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
US20120045504A1 (en) * 2009-04-14 2012-02-23 Kathryn Whitehead oral drug devices and drug formulations
SG176145A1 (en) 2009-05-18 2011-12-29 Sigmoid Pharma Ltd Composition comprising oil drops
CN101703486B (zh) * 2009-11-24 2011-11-09 上海复旦复华药业有限公司 一种氟他胺片剂及其制备方法
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN102119931B (zh) * 2011-02-21 2013-02-13 寿光富康制药有限公司 一种盐酸二甲双胍缓释片及其制备方法
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
JP6210640B2 (ja) * 2014-06-19 2017-10-11 大原薬品工業株式会社 ホリナートカルシウム含有錠
PL3215127T3 (pl) 2014-11-07 2021-05-17 Sublimity Therapeutics Limited Kompozycje zawierające cyklosporynę
GB201511284D0 (en) * 2015-06-26 2015-08-12 Univ Witwatersrand Jhb An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
JP2017210493A (ja) * 2017-09-08 2017-11-30 大原薬品工業株式会社 ホリナートカルシウム含有錠
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
JP2021036003A (ja) * 2020-12-05 2021-03-04 大原薬品工業株式会社 ホリナートカルシウム含有錠
CN117363320B (zh) * 2023-12-07 2024-02-13 黑龙江省鑫博鑫交通科技有限公司 一种公路用融雪剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
JPH08283146A (ja) * 1995-10-23 1996-10-29 Boehringer Mannheim Gmbh 成形され、圧縮された徐放性単位投薬形態の調製法およびこうして得られた圧縮単位投薬形態
DK0996429T3 (da) * 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1183014T3 (da) 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse

Also Published As

Publication number Publication date
JP2004534833A (ja) 2004-11-18
JP4657601B2 (ja) 2011-03-23
CA2451379A1 (en) 2003-01-09
US7727551B2 (en) 2010-06-01
DE60205749D1 (de) 2005-09-29
ITMI20011337A0 (it) 2001-06-26
PT1401501E (pt) 2005-10-31
ITMI20011337A1 (it) 2002-12-26
DE60205749T2 (de) 2006-03-09
EP1401501A1 (de) 2004-03-31
EP1401501B1 (de) 2005-08-24
CA2451379C (en) 2010-04-06
WO2003002151A1 (en) 2003-01-09
DK1401501T3 (da) 2006-01-09
US20040213844A1 (en) 2004-10-28
ES2248576T3 (es) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
NZ527157A (en) Compositions for delivering bisphosphonates
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
HUP0400850A2 (hu) Orálisan adagolható gyógyászati készítmények
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
SE0203817D0 (sv) New composition
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401501

Country of ref document: EP